Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    CEL-SCI Corporation

    AMEX: CVM · Real-Time Price · USD
    2.49
    -0.03 (-1.19%)
    At close: Jul 03, 2025, 2:35 PM
    2.43
    -2.41%
    After-hours: Jul 03, 2025, 04:36 PM EDT
    -1.19%
    Bid 2.43
    Market Cap 12.79M
    Revenue (ttm) n/a
    Net Income (ttm) -20.04M
    EPS (ttm) -12.3
    PE Ratio (ttm) -0.2
    Forward PE -0.08
    Analyst n/a
    Ask 2.55
    Volume 190,040
    Avg. Volume (20D) 201,832
    Open 2.54
    Previous Close 2.52
    Day's Range 2.42 - 2.71
    52-Week Range 1.98 - 66.60
    Beta 0.26

    About CVM

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CVM
    Website n/a
    Full Company Profile

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -45.45%
    CEL-SCI shares are trading lower following announc... Unlock content with Pro Subscription
    1 month ago
    -11.74%
    CEL-SCI shares are trading lower after the company announced a proposed public offering.
    news image

    2 weeks ago · businesswire.com

    FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HNSCC--FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine.

    news image

    1 month ago · businesswire.com

    CEL-SCI Announces Closing of Public Offering

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of public offering.

    news image

    1 month ago · businesswire.com

    CEL-SCI Announces Pricing of Public Offering

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of public offering.

    news image

    1 month ago · businesswire.com

    CEL-SCI Announces Proposed Public Offering

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces proposed public offering.

    news image

    1 month ago · businesswire.com

    CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI'S Multikine investigational cancer medicine potentially available for commercialization by summer 2025 in Saudi Arabia.

    news image

    1 month ago · businesswire.com

    CEL-SCI Announces Combination of Common Stock

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces combination of common stock.

    news image

    1 month ago · businesswire.com

    CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal second quarter 2025 financial results.

    news image

    2 months ago · businesswire.com

    CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market.

    news image

    2 months ago · businesswire.com

    New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

    VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--New study in the scientific journal “Cancer Cell” supports CEL-SCI's strategy to seek early approval for Multikine.

    Add to Watchlist